AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Protagonist Therapeutics Inc (NASDAQ:PTGX)
112.86 USD
+1.420 1.274%Sponsored Reports
Loading...
| Previous Close (in USD) | 111.44 |
|---|---|
| Change | +1.420 1.274% |
| 52 W H/L (in USD) | 60.600/27.000 |
| EBITDA (in USD) | 28.053M |
| PE Ratio | 57.04 |
| Volume | 1533672 |
| Diluted Eps TTM | 0.78 |
| Total Assets (in USD) | 744.725M |
|---|---|
| Total Liabilities (in USD) | 69.43M |
| Revenue TTM (in USD) | 207.801M |
| Cash (in USD) | 97.249M |
| Market Cap (in USD) | 2,757.579 M |
| Revenue Per Share TTM | 3.347 |
| Gross Profit TTM (in USD) | 207.801M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
7707 Gateway Boulevard, Newark, CA, United States, 94560
510 474 0170
Employees: 124
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Dinesh V. Patel Ph.D. | CEO, Pres, Sec. & Director | 1957 |
| 2. | Dr. David Y. Liu Ph.D. | Chief R&D Strategy Officer | 1950 |
| 3. | Dr. Suneel K. Gupta Ph.D. | Chief Devel. Officer | 1958 |
| 4. | Dr. Richard S. Shames | Clinical Advisor | 1960 |
| 5. | Mr. Asif Ali | Exec. VP & Chief Financial Officer | NA |
| 6. | Mr. Mohammad Masjedizadeh | Exec. VP & CTO | NA |
| 7. | Mr. Matthew M. Gosling | Exec. VP & Gen. Counsel | 1971 |
| 8. | Ms. Carena Spivey | Exec. Director of HR | NA |
| 9. | Dr. Ashok Bhandari Ph.D. | Sr. VP of Discovery Chemistry & Process Research | 1964 |
| 10. | Dr. Scott Eric Plevy M.D. | Exec. VP and Therapeutic Head of Gastroenterology | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -127.393M | -125.551M | -64.845M | -77.878M | -39.723M |
| Minority Interest | - | - | - | - | - |
| Net Income | -123.413M | -122.627M | -66.15M | -77.187M | -38.924M |
| Selling General Administrative | 31.739M | 27.196M | 18.638M | 15.749M | 13.697M |
| Gross Profit | 26.581M | 27.357M | 28.628M | 0.231M | 30.925M |
| Reconciled Depreciation | 3.369M | 2.775M | 2.564M | 2.495M | 0.527M |
| Ebit | -134.742M | -125.845M | -64.516M | -80.521M | -42.796M |
| Ebitda | -131.373M | -125.551M | -63.662M | -77.709M | -42.269M |
| Depreciation And Amortization | 3.369M | 0.294M | 0.854M | 2.812M | 0.527M |
| Operating Income | -131.373M | -125.845M | -64.516M | -80.521M | -42.269M |
| Other Operating Expenses | 157.954M | 153.202M | 93.144M | 80.752M | 73.194M |
| Interest Expense | 3.369M | 2.481M | 0.598M | 0.169M | 0M |
| Tax Provision | 0M | 0M | 1.305M | -0.691M | -0.799M |
| Interest Income | 4.06M | 0.443M | 0.9M | 2.813M | 2.546M |
| Net Interest Income | 4.06M | 0.443M | 0.302M | 2.644M | 2.546M |
| Income Tax Expense | -3.98M | -2.924M | 1.305M | -0.691M | -0.799M |
| Total Revenue | 26.581M | 27.357M | 28.628M | 0.231M | 30.925M |
| Total Operating Expenses | 157.954M | 153.202M | 93.144M | 80.752M | 73.194M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | 3.98M | 0.294M | -0.329M | 2.643M | 2.546M |
| Net Income From Continuing Ops | -127.393M | -125.551M | -66.15M | -77.187M | -38.924M |
| Net Income Applicable To Common Shares | -127.393M | -125.551M | -66.15M | -77.187M | -38.924M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Total Assets | 744.725M | 357.951M | 247.928M | 347.695M | 324.468M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 4.238M | 13.96M | 0.042M | 0.975M | 0.311M |
| Total Liab | 69.43M | 21.274M | 784.683M | 47.674M | 44.862M |
| Total Stockholder Equity | 675.295M | 336.677M | -536.755M | -409.362M | -283.811M |
| Other Current Liab | 23.693M | 19.358M | 25.024M | 38.615M | 21.23M |
| Common Stock | 0.001M | 0.001M | - | - | - |
| Capital Stock | 0.001M | 0.001M | 0M | 0M | 0M |
| Retained Earnings | -340.522M | -615.71M | -536.755M | -409.362M | -283.811M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0.225M | 0.225M | 0.45M |
| Cash | 97.249M | 186.727M | 125.744M | 123.665M | 117.358M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 47.398M | 21.274M | 31.179M | 44.016M | 40.241M |
| Current Deferred Revenue | 18.891M | 0.003M | - | 1.601M | 14.477M |
| Net Debt | -86.383M | -185.586M | -122.088M | -117.807M | -111.399M |
| Short Term Debt | 0.51M | 1.141M | 2.515M | 2.2M | 1.459M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 10.866M | 1.141M | 3.656M | 5.858M | 5.959M |
| Other Stockholder Equity | 1015.898M | 952.491M | 0.359M | 0.299M | -0.028M |
| Property Plant Equipment | - | - | 1.565M | 6.734M | 1.462M |
| Total Current Assets | 591.641M | 355.577M | 237.355M | 340.736M | 315.606M |
| Long Term Investments | 140.252M | - | - | 0M | 2M |
| Short Term Investments | 321.664M | 154.89M | 111.611M | 203.235M | 188.451M |
| Net Receivables | 168.49M | 10.332M | 0.052M | 4.358M | 3.51M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | -10.332M | -0.094M | 8.503M | 3.976M |
| Accounts Payable | 1.615M | 0.772M | 3.64M | 1.6M | 3.075M |
| Accumulated Other Comprehensive Income | -0.082M | -0.105M | -0.359M | -0.299M | 0.028M |
| Non Currrent Assets Other | 0.225M | 0.225M | 5.947M | 0.225M | 0.45M |
| Non Current Assets Total | 153.084M | 2.374M | 10.573M | 6.959M | 8.862M |
| Capital Lease Obligations | 10.866M | 1.141M | 3.656M | 5.858M | 5.959M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 92.263M | -14.759M | -90.494M | -52.743M | 2.699M |
| Total Cashflows From Investing Activities | 91.468M | -15.86M | -90.965M | -53.71M | 2.213M |
| Total Cash From Financing Activities | 18.838M | 129.923M | 247.626M | 46.036M | 24.115M |
| Net Income | -127.393M | -125.551M | -66.15M | -77.187M | -38.924M |
| Change In Cash | 2.079M | 6.072M | 84.352M | -49.227M | -23.796M |
| Begin Period Cash Flow | 123.89M | 117.818M | 33.466M | 82.693M | 106.489M |
| End Period Cash Flow | 125.969M | 123.89M | 117.818M | 33.466M | 82.693M |
| Total Cash From Operating Activities | -108.137M | -107.865M | -72.484M | -41.527M | -49.947M |
| Depreciation | 3.369M | 2.775M | 2.564M | 2.495M | 0.527M |
| Other Cashflows From Investing Activities | - | - | - | -52.743M | 2.699M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | 3.853M |
| Sale Purchase Of Stock | 4.448M | 130.112M | 216.102M | 36.271M | 2.442M |
| Other Cashflows From Financing Activities | 4.285M | 6.094M | 2.785M | 11.544M | 0.934M |
| Capital Expenditures | 0.795M | 1.101M | 0.471M | 0.967M | 0.486M |
| Change In Working Capital | -7.766M | -3.314M | -19.016M | 26.144M | -18.017M |
| Other Non Cash Items | -0.549M | 1.83M | 0.781M | -0.557M | 0.206M |
| Free Cash Flow | -108.932M | -108.966M | -72.955M | -42.494M | -50.433M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core S&P Small-Cap ETF | 1 year ago | 3614702 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1965270 |
| 3. | iShares Russell 2000 ETF | 1 year ago | 1467921 |
| 4. | T. Rowe Price Health Sciences | 1 year ago | 993204 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 913689 |
| 6. | UBS: US Equity Small Cap Growth | 1 year ago | 744872 |
| 7. | Fidelity Small Cap Index | 1 year ago | 579241 |
| 8. | iShares S&P Small-Cap 600 Growth ETF | 1 year ago | 532299 |
| 9. | SPDR® S&P Biotech ETF | 1 year ago | 529063 |
| 10. | iShares Russell 2000 Growth ETF | 1 year ago | 529007 |
| 11. | SPDR® Portfolio S&P 600™ Sm Cap ETF | 1 year ago | 514684 |
| 12. | Avantis US Small Cap Value ETF | 1 year ago | 432457 |
| 13. | Fidelity Select Biotechnology | 1 year ago | 430113 |
| 14. | Vanguard Tax-Managed Small Cap Adm | 1 year ago | 403401 |
| 15. | iShares Biotechnology ETF | 1 year ago | 363999 |
| 16. | State St Russell Sm/Mid Cp® Indx SL Cl I | 1 year ago | 334593 |
| 17. | Fidelity Extended Market Index | 1 year ago | 330232 |
| 18. | Vanguard Russell 2000 ETF | 1 year ago | 296579 |
| 19. | SPDR® S&P 600 Small Cap Growth ETF | 1 year ago | 285834 |
| 20. | Schwab US Small-Cap ETF™ | 1 year ago | 282631 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 9736767 |
| 2. | Farallon Capital Management, L.L.C. | 1 year ago | 5930006 |
| 3. | RTW INVESTMENTS, LLC | 1 year ago | 5719415 |
| 4. | Vanguard Group Inc | 1 year ago | 4277218 |
| 5. | Deep Track Capital, LP | 1 year ago | 3000000 |
| 6. | State Street Corp | 1 year ago | 2706619 |
| 7. | Bvf Inc | 1 year ago | 2575015 |
| 8. | Johnson & Johnson | 1 year ago | 2449183 |
| 9. | Pacer Advisors, INC. | 1 year ago | 1876466 |
| 10. | Jefferies Financial Group Inc | 1 year ago | 1489495 |
| 11. | T. Rowe Price Associates, Inc. | 1 year ago | 1392652 |
| 12. | Geode Capital Management, LLC | 1 year ago | 1377063 |
| 13. | Perceptive Advisors LLC | 1 year ago | 1091271 |
| 14. | Wellington Management Company LLP | 1 year ago | 987370 |
| 15. | ADAR1 Capital Management LLC | 1 year ago | 939669 |
| 16. | Woodline Partners LP | 1 year ago | 897699 |
| 17. | Amvescap Plc. | 1 year ago | 738952 |
| 18. | American Century Companies Inc | 1 year ago | 685824 |
| 19. | Northern Trust Corp | 1 year ago | 628580 |
| 20. | Charles Schwab Investment Management Inc | 1 year ago | 557718 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...